AI Science Tracker
EN

Machine learning nominates drug exposures inversely associated with Parkinson risk

Université Paris-Saclay; Inserm · 29 Aug 2022 · medicine

Discovery

Machine learning nominates drug exposures inversely associated with Parkinson risk

Source check: Source checked. Not independent scientific confirmation.

Finding: LASSO-based screening evaluated historical prescriptions in 40,760 Parkinson cases and 176,395 controls in French health records. Sulfonamide diuretics, especially furosemide, produced the most robust inverse-association signal. Exposure windows preceded diagnosis by years to reduce reverse causation, but confounding and prodromal changes remain possible. These observational hypotheses do not establish prevention, treatment efficacy or a reason to alter medication.

Technology: LASSO logistic regression; repeated sample splitting

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Cross-validated LASSO selects drug/covariate associations in one half-sample; logistic effects are estimated in the other and aggregated across repeated splits.
Test and result
Retrospective nested case-control screening with 500 repeated split-selection/estimation cycles and sensitivity analyses.
Limitation / still unknown
Causality, residual confounding, reverse causation and preventive/treatment efficacy remain unestablished.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10087353/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Primary full paper relevant model Methods, study Results and limitations; exact primary front-matter identity and Europe PMC metadata checked..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.